[FG] Heim Markus

Liao, Jia et al. (2025) ‘Effects of sodium–glucose co-transporter inhibitors on individual clinical endpoints and quality of life’, ESC Heart Failure, 12(2), pp. 1271–1282. Available at: https://doi.org/10.1002/ehf2.15136.

Bergman, David et al. (2025) ‘Autoimmune Thyroid Diseases and Microscopic Colitis: A Nationwide Matched Case-Control Study in Sweden’, The Journal of Clinical Endocrinology & Metabolism [Preprint]. Available at: https://doi.org/10.1210/clinem/dgaf140.

Bergman, David et al. (2025) ‘Colectomy in microscopic colitis: a rare indication’, Gut, 74(3), pp. 506–508. Available at: https://doi.org/10.1136/gutjnl-2024-333505.

Gaechter, Pascal et al. (2025) ‘Hospitalizations in people with down syndrome across age groups: a population-based cohort study in Switzerland’, eClinicalMedicine, 80, p. 103062. Available at: https://doi.org/10.1016/j.eclinm.2024.103062.

Ebrahimi, Fahim and Forss, Anders (2025) ‘The power of real-world data: insights into incident IBD populations in the modern era’, Journal of Crohn’s and Colitis, 19(1). Available at: https://doi.org/10.1093/ecco-jcc/jjaf013.

Kaldjob-Heinrich, Louise et al. (2025) ‘Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects’, Gastro Hep Advances, 4. Available at: https://doi.org/10.1016/j.gastha.2024.11.006.

Müller, Miryam et al. (2025) ‘Human-correlated genetic models identify precision therapy for liver cancer’, Nature [Preprint]. Available at: https://doi.org/10.1038/s41586-025-08585-z.

Vujasinovic, Miroslav et al. (2025) ‘Metabolic Dysfunction-Associated Steatotic Liver Disease and Pancreatic Disease—A Population-Based Nationwide Cohort and Sibling-Controlled Study’, United European Gastroenterology Journal [Preprint]. Available at: https://doi.org/10.1002/ueg2.12761.

Chancellor, Andrew et al. (2024) ‘The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells’, Immunity. 18.12.2024, 58(2), pp. 431–447.e10. Available at: https://doi.org/10.1016/j.immuni.2024.11.019.

Bergman, D. et al. (2024) ‘Psychiatric Disorders among 5,800 Patients with Microscopic Colitis: A Nationwide Population-Based Matched Cohort Study’, American Journal of Gastroenterology, 119(12), pp. 2516–2525. Available at: https://doi.org/10.14309/ajg.0000000000002955.

Ebrahimi, Fahim et al. (2024) ‘Risk of Major Adverse Cardiovascular Outcomes in Families with MASLD: A Population-Based Multigenerational Cohort Study’, Circulation: Cardiovascular Quality and Outcomes, 17(11). Available at: https://doi.org/10.1161/CIRCOUTCOMES.124.010912.

Ebrahimi, Fahim and Forss, Anders (2024) ‘Editorial: Advanced glycation end products - a dietary culprit for IBD in the genetically susceptible?’, Alimentary Pharmacology and Therapeutics, 60(10), pp. 1449–1450. Available at: https://doi.org/10.1111/apt.18240.

Sun, Jiangwei et al. (2024) ‘Bidirectional association between inflammatory bowel disease and type 1 diabetes: a nationwide matched cohort and case-control study’, The Lancet Regional Health - Europe, 46. Available at: https://doi.org/10.1016/j.lanepe.2024.101056.

Zhang, Xiaonan et al. (2024) ‘Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib’, eBioMedicine, 109. Available at: https://doi.org/10.1016/j.ebiom.2024.105368.

Sun, Jiangwei et al. (2024) ‘Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study’, Gut. 06.01.2024, 73(11). Available at: https://doi.org/10.1136/gutjnl-2023-331632.

Bergman, David et al. (2024) ‘Inflammatory eye disease is a risk factor for future microscopic colitis: A nationwide population-based matched case control study’, United European Gastroenterology Journal, 12(8), pp. 1081–1090. Available at: https://doi.org/10.1002/ueg2.12623.

Czupryniak, L. et al. (2024) ‘Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action’, Diabetes, Obesity and Metabolism, 26(10), pp. 4165–4177. Available at: https://doi.org/10.1111/dom.15789.

Ebrahimi, Fahim et al. (2024) ‘Birth Weight, Gestational Age, and Risk of Pediatric-Onset MASLD’, JAMA network open, 7(9), p. e2432420. Available at: https://doi.org/10.1001/jamanetworkopen.2024.32420.

Forss, Anders et al. (2024) ‘Diverticular disease and risk of incident major adverse cardiovascular events: a nationwide matched cohort study’, European Heart Journal - Quality of Care and Clinical Outcomes [Preprint]. Available at: https://doi.org/10.1093/ehjqcco/qcae074.

Sun, Jiangwei et al. (2024) ‘Risk of heart failure in inflammatory bowel disease: a Swedish population-based study’, European Heart Journal, 45(28), pp. 2493–2504. Available at: https://doi.org/10.1093/eurheartj/ehae338.

Forss, Anders et al. (2024) ‘Eosinophilic esophagitis and risk of incident major adverse cardiovascular events: a nationwide matched cohort study’, Esophagus, 21(3), pp. 365–373. Available at: https://doi.org/10.1007/s10388-024-01066-8.

Radu, Pompilia et al. (2024) ‘Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection’, Cancers, 16. Available at: https://doi.org/10.3390/cancers16142573.

Ebrahimi, Fahim, Andereggen, Lukas and Christ, Emanuel R. (2024) ‘Morbidities and mortality among hospitalized patients with hypopituitarism: Prevalence, causes and management’, Reviews in Endocrine and Metabolic Disorders, 25(3), pp. 599–608. Available at: https://doi.org/10.1007/s11154-024-09888-8.

Blukacz, Lauriane et al. (2024) ‘Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC’, Hepatology Communications, 8. Available at: https://doi.org/10.1097/HC9.0000000000000437.

Yang, Wen et al. (2024) ‘Risk of major adverse liver outcomes among first-degree relatives of individuals with MASLD’, Liver International. 22.02.2024, 44(5), pp. 1253–1264. Available at: https://doi.org/10.1111/liv.15874.

Ebrahimi, Fahim and Ludvigsson, Jonas F. (2024) ‘Reply to: “Familial clustering of MASLD: Rethinking strategies for population screening”’, Journal of Hepatology. 06.03.2024, 80(6), pp. e291–e292. Available at: https://doi.org/10.1016/j.jhep.2024.02.027.

Sun, Jiangwei et al. (2024) ‘Long-term risk of myocarditis in patients with inflammatory bowel disease: a nationwide cohort study in Sweden’, American Journal of Gastroenterology. 19.03.2024, p. Online ahead of print. Available at: https://doi.org/10.14309/ajg.0000000000002701.

Bergman, D. et al. (2024) ‘Microscopic Colitis and Risk of Incident Psoriasis: A Nationwide Population-Based Matched Cohort Study’, Clinical Epidemiology, 16, pp. 213–225. Available at: https://doi.org/10.2147/CLEP.S454677.

Schaeffer, Sofia et al. (2024) ‘Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease’, Frontiers in Network Physiology, 4. Available at: https://doi.org/10.3389/fnetp.2024.1458665.

Ebrahimi, Fahim et al. (2023) ‘Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study’, Journal of Hepatology, 79(6), pp. 1374–1384. Available at: https://doi.org/10.1016/j.jhep.2023.08.018.

Ebrahimi F et al. (2023) ‘Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease – A Population-based Cohort Study’, Clinical Gastroenterology and Hepatology, 21(13), pp. 3346–3355.e19. Available at: https://doi.org/10.1016/j.cgh.2023.05.013.

Hepprich, Matthias, Ebrahimi, Fahim and Christ, Emanuel (2023) ‘Dyslipidaemia and growth hormone deficiency – A comprehensive review’, Best Practice and Research: Clinical Endocrinology and Metabolism, 37(6). Available at: https://doi.org/10.1016/j.beem.2023.101821.

Simon, Tracey G. et al. (2023) ‘Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study’, Cardiovascular Diabetology, 22(1). Available at: https://doi.org/10.1186/s12933-023-02070-5.

Mossmann, Dirk et al. (2023) ‘Arginine reprograms metabolism in liver cancer via RBM39’, Cell, 186(23), pp. 5068–5083.e23. Available at: https://doi.org/10.1016/j.cell.2023.09.011.

Bergman, David et al. (2023) ‘Microscopic colitis and risk of incident rheumatoid arthritis: A nationwide population-based matched cohort study’, Alimentary Pharmacology and Therapeutics, 58(10), pp. 1028–1040. Available at: https://doi.org/10.1111/apt.17708.

Borisov, Angel N. et al. (2023) ‘Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS’, Journal of Clinical Endocrinology and Metabolism, 108(11), pp. 2940–2949. Available at: https://doi.org/10.1210/clinem/dgad249.

Nikolaou, Kostas C. et al. (2023) ‘Inflammation-induced TRIM21 represses hepatic steatosis by promoting the ubiquitination of lipogenic regulators’, JCI Insight, 8(21). Available at: https://doi.org/10.1172/jci.insight.164694.

Ebrahimi Fahim et al. (2023) ‘Antibiotic use and development of nonalcoholic fatty liver disease: A population-based case–control study’, Liver International. 30.06.2023, 43(10), pp. 2186–2197. Available at: https://doi.org/10.1111/liv.15663.

Shang, Ying et al. (2023) ‘Risk of infections in non-alcoholic fatty liver disease: A nationwide population-based cohort study’, Liver International, 43(10), pp. 2142–2152. Available at: https://doi.org/10.1111/liv.15680.

Sun, Jiangwei et al. (2023) ‘Statin use and risk of colorectal cancer in patients with inflammatory bowel disease’, eClinicalMedicine, 63. Available at: https://doi.org/10.1016/j.eclinm.2023.102182.

Ebrahimi, Fahim et al. (2023) ‘Colchicine for the secondary prevention of cardiovascular events’, Cochrane Database of Systematic Reviews. 29.08.2023, 2023(8). Available at: https://doi.org/10.1002/14651858.CD014808.

Sun J et al. (2023) ‘Long-term Risk of Stroke in Patients with Inflammatory Bowel Disease: A Population-Based, Sibling-Controlled Cohort Study, 1969-2019’, Neurology, 101(6), pp. E653–E664. Available at: https://doi.org/10.1212/WNL.0000000000207480.

Ebrahimi F and Forss A (2023) ‘Editorial: Antibiotics and risk of IBD—Can we close the books?’, Alimentary Pharmacology and Therapeutics. John Wiley and Sons Inc, 58(2). Available at: https://doi.org/10.1111/apt.17563.

Ebrahimi F and Christ E (2023) ‘Why do patients with hypopituitarism still present an increased mortality?’, Annales d’Endocrinologie, 84(2), pp. 285–290. Available at: https://doi.org/10.1016/j.ando.2023.02.002.

Pu, W. et al. (2023) ‘Bipotent transitional liver progenitor cells contribute to liver regeneration’, Nature Genetics, 55(4), pp. 651–664. Available at: https://doi.org/10.1038/s41588-023-01335-9.

Pop, Oltin-Tiberiu et al. (2023) ‘AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells’, Cellular and Molecular Gastroenterology and Hepatology, 16(1), pp. 17–37. Available at: https://doi.org/10.1016/j.jcmgh.2023.03.007.

Pop, Oltin-Tiberiu et al. (2023) ‘AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells’, Cellular and Molecular Gastroenterology and Hepatology, 16(1), pp. 17–37. Available at: https://doi.org/10.1016/j.jcmgh.2023.03.007.

Hauser, Stephanie Isabelle et al. (2022) ‘Trends and outcomes of children, adolescents, and adults hospitalized with inherited metabolic disorders: A population-based cohort study’, JIMD Reports, 63(6), pp. 581–592. Available at: https://doi.org/10.1002/jmd2.12320.

Suslov A, Heim MH and Wieland S (2022) ‘Studying Hepatitis Virus-Host Interactions in Patient Liver Biopsies’, Viruses, 14(11). Available at: https://doi.org/10.3390/v14112490.

Ebrahimi, Fahim et al. (2022) ‘Lifetime risk and health-care burden of diabetic ketoacidosis: A population-based study’, Frontiers in Endocrinology, 13. Available at: https://doi.org/10.3389/fendo.2022.940990.

Ebrahimi F, Semela D and Heim M (2022) ‘Impact of propofol sedation on the diagnostic accuracy of hepatic venous pressure gradient measurements in patients with cirrhosis’, Hepatology International, 16(4), pp. 817–823. Available at: https://doi.org/10.1007/s12072-021-10261-z.

Christ E et al. (2022) ‘Evaluation of type 2 diabetes care management in nine primary care practices before and after implementation of the Criteria of Good Disease Management of Diabetes established by the Swiss Society of Endocrinology and Diabetology’, Swiss Medical Weekly, 152(2930), p. w30197. Available at: https://doi.org/10.4414/SMW.2022.w30197.

Donners R et al. (2022) ‘Computed tomography (CT) and magnetic resonance imaging (MRI) of diffuse liver disease: a multiparametric predictive modelling algorithm can aid categorization of liver parenchyma’, Quantitative Imaging in Medicine and Surgery, 12(2), pp. 1186–1197. Available at: https://doi.org/10.21037/qims-21-384.

Gallon J et al. (2022) ‘Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma’, Molecular Oncology, 16(3), pp. 665–682. Available at: https://doi.org/10.1002/1878-0261.13154.

Kutz, Alexander et al. (2022) ‘Association of Interprofessional Discharge Planning Using an Electronic Health Record Tool With Hospital Length of Stay Among Patients with Multimorbidity: A Nonrandomized Controlled Trial’, Jama Network Open, 5(9), p. e2233667. Available at: https://doi.org/10.1001/jamanetworkopen.2022.33667.

Lett, Martin J et al. (2022) ‘Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells’, Gut, 71(12), pp. 2526–2538. Available at: https://doi.org/10.1136/gutjnl-2021-324478.

Lett, Martin J et al. (2022) ‘Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells’, Gut, 71(12), pp. 2526–2538. Available at: https://doi.org/10.1136/gutjnl-2021-324478.

Ng, Charlotte K. Y. et al. (2022) ‘Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages’, Nature Communications, 13(1), p. 2436. Available at: https://doi.org/10.1038/s41467-022-29960-8.

Park, Sujin et al. (2022) ‘Transcription factors TEAD2 and E2A globally repress acetyl-CoA synthesis to promote tumorigenesis’, Molecular Cell, 82(22), pp. 4246–4261.e11. Available at: https://doi.org/10.1016/j.molcel.2022.10.027.

Suter, Polina et al. (2022) ‘Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model’, PLoS computational biology, 18(9), p. e1009767. Available at: https://doi.org/10.1371/journal.pcbi.1009767.

Chen Q. et al. (2021) ‘Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses’, Nature Communications, 12(1), p. 4882. Available at: https://doi.org/10.1038/s41467-021-25218-x.

Ding L et al. (2021) ‘Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis’, Nature Metabolism, 3(12), pp. 1648–1661. Available at: https://doi.org/10.1038/s42255-021-00489-2.

Boldanova T et al. (2021) ‘Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization’, Cell Reports Medicine, 2(11), p. 100444. Available at: https://doi.org/10.1016/j.xcrm.2021.100444.

Meier MA et al. (2021) ‘Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load’, Journal of Hepatology, 75(4), pp. 840–847. Available at: https://doi.org/10.1016/j.jhep.2021.04.051.

Vosshenrich J et al. (2021) ‘Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models’, European Radiology, 31(6), pp. 4367–4376. Available at: https://doi.org/10.1007/s00330-020-07511-3.

Suslov A et al. (2021) ‘Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity’, Journal of Hepatology, 74(4), pp. 794–800. Available at: https://doi.org/10.1016/j.jhep.2020.11.003.

Janiaud P et al. (2021) ‘Association of Convalescent Plasma Treatment with Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis’, JAMA - Journal of the American Medical Association, 325(12), pp. 1185–1195. Available at: https://doi.org/10.1001/jama.2021.2747.

Nuciforo S and Heim MH (2021) ‘Organoids to model liver disease’, JHEP Reports, 3(1), p. 100198. Available at: https://doi.org/10.1016/j.jhepr.2020.100198.

Coto-Llerena M et al. (2021) ‘Interferon lambda 4 can directly activate human CD19+ B cells and CD8+ T cells’, Life Science Alliance, 4(1). Available at: https://doi.org/10.26508/LSA.201900612.

Fahim Ebrahimi and Christine Bernsmeier (2021) ‘Häufige Lebererkrankungen – Früherkennung rettet Leben.’, Der Allgemeinarzt [Preprint].

Gao, Ruize et al. (2021) ‘USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis’, Oncogenesis, 10(7), p. 52. Available at: https://doi.org/10.1038/s41389-021-00338-7.

Sorrentino G et al. (2020) ‘Mechano-modulatory synthetic niches for liver organoid derivation’, Nature Communications, 11(1), p. 3416. Available at: https://doi.org/10.1038/s41467-020-17161-0.

Hess, Gabriel Fridolin et al. (2020) ‘Hepatectomy of a Hepatocellular Carcinoma after SIRT in a Cirrhotic Liver’, Archives of Surgery and Clinical Case Reports, 3(3). Available at: https://doi.org/10.29011/2689-0526.100129.

Kinast V et al. (2020) ‘C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle’, Journal of Hepatology, 73(3), pp. 549–558. Available at: https://doi.org/10.1016/j.jhep.2020.03.047.

Roelens, Maroussia et al. (2020) ‘All-cause mortality and causes of death in the swiss hepatitis C cohort study (SCCS)’, Open Forum Infectious Diseases, 7(8). Available at: https://doi.org/10.1093/ofid/ofaa308.

Goossens N, Toso C and Heim MH (2020) ‘Management of hepatocellular carcinoma: SASL expert opinion statement’, Swiss Medical Weekly, 150(32), p. w20296. Available at: https://doi.org/10.4414/smw.2020.20296.

Andreozzi M et al. (2020) ‘Corrigendum to “HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models” [Neoplasia 18 (2016) 724–731] (Neoplasia (2016) 18(12) (724–731), (S1476558616301634), (10.1016/j.neo.2016.10.002))’, 22(7). Available at: https://doi.org/10.1016/j.neo.2020.04.004.

Tran HTL et al. (2020) ‘OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease’, PLoS ONE, 15(7 July), p. e0236447. Available at: https://doi.org/10.1371/journal.pone.0236447.

Bertisch, B. et al. (2020) ‘Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?’, Clinical Infectious Diseases, 70(4), pp. 653–659. Available at: https://doi.org/10.1093/cid/ciz270.

Brenig R et al. (2020) ‘Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis’, Life Science Alliance, 3(1). Available at: https://doi.org/10.26508/lsa.201900465.

Di Blasi D. et al. (2020) ‘Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma’, Cellular and Molecular Gastroenterology and Hepatology, 9(2), pp. 195–218. Available at: https://doi.org/10.1016/j.jcmgh.2019.08.004.

Fahim Ebrahimi and Christine Bernsmeier (2020) ‘Häufige Lebererkrankungen – Diagnostik und Therapie.’, Leading Opinions Innere Medizin [Preprint].

Blumer T. et al. (2019) ‘Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors’, Hepatology Communications, 3(7), pp. 971–986. Available at: https://doi.org/10.1002/hep4.1365.

Flecken T et al. (2019) ‘Mapping the heterogeneity of histone modifications on hepatitis B virus DNA using liver needle biopsies obtained from chronically infected patients’, Journal of Virology, 93(9). Available at: https://doi.org/10.1128/JVI.02036-18.

Wieland SF and Heim MH (2019) ‘The IFN-λ Pony Express’. Nature Publishing GroupHoundmillsBasingstoke, HampshireRG21 6XS, 20(5). Available at: https://doi.org/10.1038/s41590-019-0362-9.

Calabrese D et al. (2019) ‘Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells.’, PloS one, 14(8), p. e0221762. Available at: https://doi.org/10.1371/journal.pone.0221762.

Ruperti-Repilado, Francisco Javier et al. (2019) ‘Danger of Herbal Tea: A Case of Acute Cholestatic Hepatitis Due to; Artemisia annua; Tea’, Frontiers in medicine, 6, p. 221. Available at: https://doi.org/10.3389/fmed.2019.00221.

Tang, Fengyuan et al. (2019) ‘LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function’, Nature Communications, 10(1), p. 5755. Available at: https://doi.org/10.1038/s41467-019-13591-7.

Broguiere N et al. (2018) ‘Growth of Epithelial Organoids in a Defined Hydrogel’, Advanced Materials, 30(43), p. e1801621. Available at: https://doi.org/10.1002/adma.201801621.

Goossens N et al. (2018) ‘Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review’, Journal of Viral Hepatitis, 25(8), pp. 920–929. Available at: https://doi.org/10.1111/jvh.12891.

Suslov A, Heim MH and Wieland S (2018) ‘New insights into HDV-induced innate immunity: MDA5 senses HDV replication’, 69(1). Available at: https://doi.org/10.1016/j.jhep.2018.03.030.

Suslov A et al. (2018) ‘Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver’, Gastroenterology, 154(6), pp. 1778–1790. Available at: https://doi.org/10.1053/j.gastro.2018.01.034.

Allgaier, H.-P. et al. (2018) ‘From Molecuar to Natural Medicine Von der molekularen Medizin bis zur Naturheilkunde 1’, Deutsche Medizinische Wochenschrift, 143(1), pp. 40–45. Available at: https://doi.org/10.1055/s-0043-123263.

Hindupur, Sravanth K. et al. (2018) ‘The protein histidine phosphatase LHPP is a tumour suppressor’, Nature, 555(7698), p. 678–+. Available at: https://doi.org/10.1038/nature26140.

Ng, C. K. Y. et al. (2018) ‘Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study’, Annals of Oncology, 29(5), pp. 1286–1291. Available at: https://doi.org/10.1093/annonc/mdy083.

Nuciforo, Sandro et al. (2018) ‘Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies’, Cell reports, 24(5), pp. 1363–1376. Available at: https://doi.org/10.1016/j.celrep.2018.07.001.

Paradiso, Viola et al. (2018) ‘Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening’, The Journal of molecular diagnostics : JMD, 20(6), pp. 836–848. Available at: https://doi.org/10.1016/j.jmoldx.2018.07.003.

Gauthiez E et al. (2017) ‘A systematic review and meta-analysis of HCV clearance’, Liver International, 37(10), pp. 1431–1445. Available at: https://doi.org/10.1111/liv.13401.

Juhling, Frank et al. (2017) ‘Hepatitis C virus-induced epigenetic changes associated with hepatocarcinogenesis persist following viral cure’. WILEY, 66.

Blumer, Tanja et al. (2017) ‘SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo’, Journal of Biological Chemistry, 292(43), pp. 17928–17938. Available at: https://doi.org/10.1074/jbc.m117.788877.